Dupilumab
Dupilumab (pronounced doo-pil-yoo-mab) is a type of biologic therapy used in the treatment of certain autoimmune diseases.
Etymology
The name "Dupilumab" is derived from the combination of "du" (meaning two in French), "pilus" (Latin for hair, referring to the two pronged approach of the drug), and "mab" (an abbreviation for monoclonal antibody).
Usage
Dupilumab is primarily used in the treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. It works by blocking the action of two proteins, interleukin-4 and interleukin-13, which are known to play a key role in the inflammatory response that occurs in these conditions.
Administration
Dupilumab is administered by subcutaneous injection, usually given every two weeks. The dosage may vary depending on the specific condition being treated and the patient's overall health status.
Side Effects
Common side effects of Dupilumab include redness, itching, and swelling at the injection site. Other potential side effects include conjunctivitis, headache, and cold sores in the mouth or on the lips.
Related Terms
- Monoclonal antibody
- Interleukin
- Autoimmune disease
- Atopic dermatitis
- Asthma
- Chronic rhinosinusitis with nasal polyps
External links
- Medical encyclopedia article on Dupilumab
- Wikipedia's article - Dupilumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski